📊 BIOX Key Takeaways
Is Bioceres Crop Solutions Corp. (BIOX) a Good Investment?
Insufficient fundamental data available for meaningful analysis. All key financial metrics including revenue, profitability, balance sheet items, and cash flow are unavailable. Unable to assess financial health, growth trends, or operational quality without core financial data.
Bioceres’ fundamentals have deteriorated sharply: fiscal 2025 revenue fell 28% to about $335 million, operating results turned negative, and the company moved from profit to a sizable net loss while carrying heavy debt and a formal going-concern warning. Although gross margin has held near 39-40%, that resilience is being overwhelmed by weak demand in Argentina, funding stress, debt acceleration, and a major foreclosure-related impairment in the December 31, 2025 period.
Why Buy Bioceres Crop Solutions Corp. Stock? BIOX Key Strengths
- Operates in agricultural chemicals sector with essential market demand
- Listed on Nasdaq indicating regulatory compliance and market access
- Bioceres indicates potential focus on biological/crop science innovation
- Gross margin remained relatively resilient at roughly 39-40%, indicating some pricing power and mix support from proprietary products
- The business generated positive operating cash flow in fiscal 2025, helped by working-capital improvement
- The company still has meaningful intangible assets, technology platforms, and market positions across crop protection, nutrition, and seeds
BIOX Stock Risks: Bioceres Crop Solutions Corp. Investment Risks
- Complete absence of revenue and profitability data prevents financial health assessment
- No balance sheet data available to evaluate liquidity or leverage position
- Inability to assess cash generation capability or sustainability
- Zero insider trading activity in last 90 days may indicate limited management confidence or inactive disclosure period
- Critical data quality issue with only 1 metric available out of comprehensive financial suite
- Substantial doubt about the company’s ability to continue as a going concern, with dependence on refinancing and restructuring
- High leverage and acute liquidity pressure, including accelerated secured notes, suspended credit lines, and large near-term maturities
- Weak growth quality: revenue has contracted sharply, profitability has collapsed, and the December 2025 period included a very large foreclosure-related impairment and deep net loss
Key Metrics to Watch
- Revenue growth rate and gross margins once reported
- Operating cash flow and free cash flow trends
- Debt-to-equity ratio and liquidity position (current ratio)
- Net profit margin and return on equity
- Research and development spending as percentage of revenue
- Operating cash flow and free cash flow relative to debt service needs
- Debt restructuring progress, current-liability reduction, and liquidity runway
Bioceres Crop Solutions Corp. (BIOX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BIOX Profit Margin, ROE & Profitability Analysis
BIOX vs Materials Sector: How Bioceres Crop Solutions Corp. Compares
How Bioceres Crop Solutions Corp. compares to Materials sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Bioceres Crop Solutions Corp. Stock Overvalued? BIOX Valuation Analysis 2026
Based on fundamental analysis, Bioceres Crop Solutions Corp. has mixed fundamental signals relative to the Materials sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Bioceres Crop Solutions Corp. Balance Sheet: BIOX Debt, Cash & Liquidity
BIOX Revenue Growth, EPS Growth & YoY Performance
BIOX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Bioceres Crop Solutions Corp. (CIK: 0001769484)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BIOX
What is the AI rating for BIOX?
Bioceres Crop Solutions Corp. (BIOX) has a Combined AI Rating of SELL from Claude (HOLD) and ChatGPT (STRONG SELL) with 49% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BIOX's key strengths?
Claude: Operates in agricultural chemicals sector with essential market demand. Listed on Nasdaq indicating regulatory compliance and market access. ChatGPT: Gross margin remained relatively resilient at roughly 39-40%, indicating some pricing power and mix support from proprietary products. The business generated positive operating cash flow in fiscal 2025, helped by working-capital improvement.
What are the risks of investing in BIOX?
Claude: Complete absence of revenue and profitability data prevents financial health assessment. No balance sheet data available to evaluate liquidity or leverage position. ChatGPT: Substantial doubt about the company’s ability to continue as a going concern, with dependence on refinancing and restructuring. High leverage and acute liquidity pressure, including accelerated secured notes, suspended credit lines, and large near-term maturities.
What is BIOX's revenue and growth?
Bioceres Crop Solutions Corp. reported revenue of N/A.
Does BIOX pay dividends?
Bioceres Crop Solutions Corp. does not currently pay dividends.
Where can I find BIOX SEC filings?
Official SEC filings for Bioceres Crop Solutions Corp. (CIK: 0001769484) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BIOX's EPS?
Bioceres Crop Solutions Corp. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BIOX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Bioceres Crop Solutions Corp. has a SELL rating with 49% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BIOX stock overvalued or undervalued?
Valuation metrics for BIOX: ROE of N/A (sector avg: 14%), net margin of N/A (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy BIOX stock in 2026?
Our dual AI analysis gives Bioceres Crop Solutions Corp. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BIOX's free cash flow?
Bioceres Crop Solutions Corp.'s operating cash flow is N/A, with capital expenditures of N/A.
How does BIOX compare to other Materials stocks?
Vs Materials sector averages: Net margin N/A (avg: 10%), ROE N/A (avg: 14%), current ratio N/A (avg: 1.6).